Speaker
Description
We develop different Systems ranging from active nanoparticles (nanobots) to 3D Bioprinted Actuators. We are interested in fundamental studies of active matter, the use of nanobots for future nanomedicine, and the bioengineering of new devices based on hybrid systems.Our group employs urease-powered nanobots as an innovative approach to treating bladder cancer. We have demonstrated that these nanobots can enhance anti-cancer drug delivery in vitro, improve the targeting of 3D bladder cancer spheroids, and sense their surrounding environment.
Additionally, we have recently reported their application in vivo, showing their ability to move inside the bladder of healthy mice, accumulate in bladder tumors, and effectively treat bladder cancer using radionuclide therapy. Our goal is to advance this technology towards clinical translation to ultimately improve patients’ lives.
